PD-1 Monoclonal Antibody, Lenvatinib and TACE in the Treatment of HCC

NCT04273100 · clinicaltrials.gov ↗

PHASE2

Phase

UNKNOWN

Status

56

Enrollment

OTHER

Sponsor class

Conditions

Hepatocellular Carcinoma Non-resectable

Interventions

COMBINATION_PRODUCT: PD-1 mAb combined with TACE and lenvatinib

Sponsor

Tianjin Medical University Cancer Institute and Hospital